Debbie Garner - Avita Medical Senior Strategy
| RCEL Stock | USD 13.23 0.02 0.15% |
Executive
Debbie Garner is Senior Strategy of Avita Medical
| Address | 28159 Avenue Stanford, Valencia, CA, United States, 91355 |
| Phone | 661 367 9170 |
| Web | https://www.avitamedical.com |
Avita Medical Management Efficiency
The company has return on total asset (ROA) of (0.4537) % which means that it has lost $0.4537 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5244) %, meaning that it created substantial loss on money invested by shareholders. Avita Medical's management efficiency ratios could be used to measure how well Avita Medical manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.33. The value of Return On Capital Employed is expected to slide to -0.38. At this time, Avita Medical's Net Current Asset Value is quite stable compared to the past year. Tangible Asset Value is expected to rise to about 4.1 M this year, although the value of Intangible Assets will most likely fall to about 462.6 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Caroline Vaughn | Rxsight | N/A | |
| CFA CPA | Axogen Inc | 50 | |
| Martha Rook | Delcath Systems | 54 | |
| Matthew CPA | Apyx Medical | 55 | |
| Robert John | CVRx Inc | N/A | |
| Michael Pisetsky | Si Bone | 46 | |
| Todd Puckett | Axogen Inc | N/A | |
| Scott Gaines | Rxsight | N/A | |
| Doris Quackenbush | Axogen Inc | N/A | |
| Sandra Pennell | Delcath Systems | 44 | |
| Jeremy Stigall | Clearpoint Neuro | 40 | |
| Julie Dewey | Treace Medical Concepts | 63 | |
| Irene Thomas | Neuropace | 55 | |
| Michael Donovan | Axogen Inc | 59 | |
| Nick Corcoran | TransMedics Group | 42 | |
| Chris Williamson | Iradimed Co | N/A | |
| Lynn Neuhardt | Iradimed Co | N/A | |
| Julie Dewey | Orthofix Medical | 63 | |
| Kelley Nicholas | Neuropace | N/A | |
| Lucas Vitale | Orthofix Medical | 47 | |
| Irina Ridley | Neuropace | 38 | |
Management Performance
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.45 |
Avita Medical Leadership Team
Elected by the shareholders, the Avita Medical's board of directors comprises two types of representatives: Avita Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avita. The board's role is to monitor Avita Medical's management team and ensure that shareholders' interests are well served. Avita Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avita Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rob Hall, Senior Resources | ||
| James Corbett, President CEO | ||
| Michael MBA, Chief Officer | ||
| Jessica Ekeberg, Investor Executive | ||
| David OToole, Chief Officer | ||
| Kathy McGee, Chief Officer | ||
| Terry Bromley, Senior Sales | ||
| Katie Bush, Senior Affairs | ||
| Donna Shiroma, General Secretary | ||
| Ron Lagerquist, Senior Affairs | ||
| David Fencil, Senior Operations | ||
| Andrew Quick, Chief Officer | ||
| Debbie Garner, Senior Strategy | ||
| JD PMP, Senior Management | ||
| Nicole Kelsey, Chief Secretary | ||
| Erin Liberto, Chief Officer |
Avita Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avita Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.45 | ||||
| Profit Margin | (0.95) % | ||||
| Operating Margin | (0.71) % | ||||
| Current Valuation | 360.4 M | ||||
| Shares Outstanding | 26.22 M | ||||
| Shares Owned By Insiders | 0.96 % | ||||
| Shares Owned By Institutions | 23.49 % | ||||
| Number Of Shares Shorted | 1.02 M | ||||
| Price To Book | 28.33 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avita Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Avita Stock please use our How to buy in Avita Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avita Medical. If investors know Avita will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avita Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.23) | Revenue Per Share 2.335 | Quarterly Revenue Growth 0.432 | Return On Assets (0.45) | Return On Equity (1.52) |
The market value of Avita Medical is measured differently than its book value, which is the value of Avita that is recorded on the company's balance sheet. Investors also form their own opinion of Avita Medical's value that differs from its market value or its book value, called intrinsic value, which is Avita Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avita Medical's market value can be influenced by many factors that don't directly affect Avita Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avita Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Avita Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avita Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.